Examples include recombinant erythropoietin (EPO) for ischaemic stroke, where EPO and EPO analogues were associated with a decrease in infarct size and an improvement in various behavioural tests using multiple stroke models (Minnerup et al., 2009). This evidence concerns the gene EPO and stroke disorder.